MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced TumorsAccesswire • 10/27/22
GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid ArthritisAccesswire • 10/27/22
MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022Accesswire • 10/21/22
MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCLBusiness Wire • 09/28/22
MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte PetersBusiness Wire • 08/31/22
MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/06/22
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022Accesswire • 07/28/22
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022Accesswire • 07/26/22
MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022Accesswire • 07/26/22
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210PRNewsWire • 06/15/22
MorphoSys Stock Skyrockets On Entering Equity Participation and License Agreements With HIBioBenzinga • 06/14/22
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210Business Wire • 06/14/22
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47Business Wire • 06/13/22
MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022Business Wire • 06/10/22
MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual MeetingsBusiness Wire • 05/12/22
MorphoSys AG (MOR) CEO Jean-Paul Kress on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/09/22
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022Accesswire • 04/28/22
Wall Street Analysts Believe MorphoSys AG Unsponsored ADR (MOR) Could Rally 213%: Here's is How to TradeZacks Investment Research • 04/12/22
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCLAccesswire • 03/22/22
